# Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

> **NCT00409578** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 1101 (actual)

## Conditions studied

- Post Acute Coronary Syndrome
- Myocardial Ischemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Aliskiren 300 mg
- **DRUG:** Valsartan 320 mg
- **DRUG:** Aliskiren/valsartan 300/320 mg

## Key facts

- **NCT ID:** NCT00409578
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 1101 (ACTUAL)
- **Last updated:** 2011-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00409578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00409578, "Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00409578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*